8-week Refinement Protocol

SR-9009 SAFETY DATA SHEET
GW0742 SAFETY DATA SHEET
ENCLOMIPHENE SAFETY DATA SHEET

The 8 Week Refinement Protocol is an extended-duration research package assembled for preclinical investigation of full-cycle metabolic and oxidative signalling, with structured post-administration endocrine assessment. It combines two non-androgenic metabolic modulators in dosing quantities sufficient for an eight-week experimental window, paired with enclomiphene for parallel investigation of baseline HPG-axis function.

The mechanistic rationale focuses on sustained engagement of REV-ERB and PPARδ pathways across the active phase. SR-9009 modulates circadian and oxidative gene expression, GW0742 upregulates fatty acid β-oxidation and mitochondrial biogenesis, and enclomiphene provides a tool for monitoring endogenous LH, FSH, and testosterone signalling throughout the protocol – particularly relevant in research models where metabolic intervention is studied in conjunction with broader endocrine parameters.

Included in this protocol:

• 2 × SR-9009 | 100 pellets, 10 mg active compound per pellet
• 2 × GW0742 | 100 pellets, 10 mg active compound per pellet
• 1 × Enclomiphene | 100 pellets, 10 mg active compound per pellet

Total: 500 pellets / 5,000 mg active compound.

Compound roles in this protocol:

SR-9009 (Stenabolic) – REV-ERB agonist supplying sustained activation of the oxidative and circadian metabolism axis across the eight-week active phase, with effects on mitochondrial biogenesis, glucose uptake, and lipid profile modulation.

GW0742 – selective PPARδ agonist contributing the fatty acid oxidation component, modulating lipid metabolism, glucose homeostasis, and endurance-related parameters across the extended duration.

Enclomiphene – selective estrogen receptor modulator included for parallel investigation of HPG-axis function, supporting research designs that integrate metabolic intervention with concurrent endocrine monitoring.

Combined research applications:

• Preclinical models of extended-duration metabolic and oxidative pathway stimulation
• Studies of mitochondrial biogenesis, β-oxidation, and lipid profile across an eight-week active phase
• Investigation of endurance and exercise capacity in long-duration murine models
• Research into adipose tissue accumulation under high-fat dietary challenge across extended stimulation
• Comparative analysis of long-duration metabolic intervention with concurrent HPG-axis assessment

This protocol is positioned as a complete research framework for extended-duration metabolic studies, designed for investigators requiring sustained PPARδ and REV-ERB engagement alongside structured endocrine monitoring. Unlike anabolic-focused protocols, this combination produces minimal HPG-axis impact during the active phase, with enclomiphene functioning as a baseline monitoring tool rather than a recovery agent.

⚠ Important Note: This product is supplied strictly for laboratory research use only. It is not approved for human consumption or therapeutic use. Not intended to diagnose, treat, cure, or prevent any disease.